Global leaders dither while disease races to Latin America
By Andrew Spiegel
You’re nearly twice as likely to die from colon cancer living in a Latin American country than you are living in the United States.
Global health leaders are trying to fix this disparity. But unfortunately, they’ve misdiagnosed the problem.
Some blame intellectual property protections for pharmaceuticals. They argue that allowing companies to patent new drugs prevents patients in developing regions from accessing lifesaving medicines. They want to eliminate patents altogether.
This strategy is certain to fail. Effective intellectual property protection and enforcement encourages medical research and development. Weakening patents would reduce access to cutting-edge cures. It’s time to take a new approach.
In September at the UN in New York, world leaders will meet to discuss non-communicable diseases. These leaders should focus on improving healthcare infrastructure in the developing world. Chronic diseases are on the rise in developing countries, and they’re ill-prepared.
Consider colon cancer. Right now, the condition is less prevalent in Latin America than in North America. In Latin America, there are 11 cases of colon cancer per 100,000 people. In North America, there are 30 cases per 100,000.
But that could soon change. Many countries are beginning to adopt more Americanized diets, which experts believe may increase one’s risk of developing colon cancer. Sales of processed foods in developing countries are growing almost 30 percent annually.
That will cause the global burden of colon cancer to nearly double by 2035. All told, non-communicable diseases will account for 70 percent of fatalities in developing countries by 2020.
The developing world lacks the resources to treat these diseases. Honduras, for instance, has only 30 doctors per 100,000 people. The United States has six times that number.
Instead of addressing these challenges, global health leaders get sidetracked by stale arguments about weakening intellectual property protections.
It costs more than $2 billion to bring a new medicine to market. Intellectual property protections help researchers earn back this investment and encourage them to take this risk again.
Without these protections, companies would scale back drug development. That would lead to fewer lifesaving treatments. Patients would suffer.
Anti-intellectual property actions wouldn’t even boost short-term access to medicines. More than 90 percent of the WHO’s list of “essential medicines” are off-patent. Intellectual property isn’t a barrier to access for people in the developing world.
But anti-IP measures and poor IP-enforcement are barriers to care. And they abound in Latin America.
Brazil, for instance, abuses “compulsory licensing.” This policy allows for the production of a patented product without approval from the patent owner.
In 2007, the government allowed Brazilian companies to reproduce the U.S. anti-retroviral Efavirenz for 77,000 patients.
That prevented its U.S. creator, Merck, from recouping the massive investments it made to create the life-extending drug. There’s no incentive for drug companies to innovate if countries can copy patented, costly drugs at the drop of a hat.
The developing world is on the brink of a chronic disease epidemic. At the upcoming UN meeting on non-communicable diseases, countries must combat it by improving healthcare infrastructure while also encouraging innovation.
Andrew Spiegel, Esq., is co-founder and executive director of the Global Colon Cancer Association and a board member of the International Alliance of Patients’ Organizations..
The viewpoints expressed above are those of the author and do not necessarily reflect those of The Independent.
How to submit an article, guest opinion piece, or letter to the editor to The Independent
Do you have something to say? Want your voice to be heard by thousands of readers? Send The Independent your letter to the editor or guest opinion piece. All submissions will be considered for publication by our editorial staff. If your letter or editorial is accepted, it will run on suindependent.com, and we’ll promote it through all of our social media channels. We may even decide to include it in our monthly print edition. Just follow our simple submission guidelines and make your voice heard:
—Submissions should be between 300 and 1,500 words.
—Submissions must be sent to editor@infowest.com as a .doc, .docx, .txt, or .rtf file.
—The subject line of the email containing your submission should read “Letter to the editor.”
—Attach your name to both the email and the document file (we don’t run anonymous letters).
—If you have a photo or image you’d like us to use and it’s in .jpg format, at least 1200 X 754 pixels large, and your intellectual property (you own the copyright), feel free to attach it as well, though we reserve the right to choose a different image.
—If you are on Twitter and would like a shout-out when your piece or letter is published, include that in your correspondence and we’ll give you a mention at the time of publication.
Articles related to “Global leaders dither while disease races to Latin America”
Hamburgers and coprophagia: There’s poop in your meat, y’all
Americanized Diet. Your words. Blame America for the dysfunctional governments in Central America. First let’s use common sense. A colonoscopy, which requires two things. A specific tool and anesthetics. Yes, important to have that specific tool free of bacteria. More important is to get people tbe COURAGE to get a colonoscopy. Oh forgot,
you need that fluid that purges system the day prior. . During tbe colonoscopy the polop can be removed. Prevention is everything. Your argument is after the fact. Try blaming the C.A. government’s lack of concern for their citizens health. START LOCAL THAEN ACT GLOBAL.